Tirzepatide is a dual-agonist research peptide that simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is extensively studied in preclinical and research models for its profound effects on glucose homeostasis, insulin sensitivity, appetite suppression, gastric emptying, and substantial body-weight reduction in obesity and type-2 diabetes models.
• Purity: ≥99% (HPLC verified)
• Sequence: 39-amino-acid linear peptide with C20 fatty diacid acyl chain
• CAS No.: 2023788-19-2
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈ (approximate, includes lipidation)
• Molecular Weight: 4813.5 g/mol
• Form: Lyophilized powder
• Solubility: Reconstitute with bacteriostatic water or sterile saline (forms clear solution)
• Storage: Freeze-dried at -20°C; reconstituted at 2–8°C for up to 30 days
• Includes: Third-party Certificate of Analysis (COA) with every order
Disclaimer: This product is sold strictly for laboratory and in-vitro research purposes only. It is not intended for human or animal consumption, medical, diagnostic, therapeutic, or veterinary use. Not evaluated by Health Canada or the FDA. The purchaser is solely responsible for ensuring compliance with all applicable laws and regulations in Quebec, Canada.
